A novel wearable device, already used on nearly 2,000 patients to slow the growth of cancerous glioblastoma brain tumors using electrical fields, is now being tested to judge its effectiveness against other types of solid tumors.

Novocure Chief Science Officer Eilon Kirson tells ISRAEL21c that the 15-year-old company’s Tumor Treating Fields (TTFields) technology is being tested on ovarian and pancreatic cancer patients and patients with cancers that have spread to the brain.

At the same time, Novocure is involved in trials to see if TTFields can extend the life of even more patients with glioblastoma, the most common form of primary brain cancer in adults. Approximately 10,000 new cases are diagnosed in the United States each year.

“Electric field-based therapy had never been used to treat cancer beyond very local therapies,” Kirson explains. “Treating entire parts of the body this way is a completely novel concept and technology, and there is no other one like it. Novocure owns the entire IP [intellectual property] portfolio for the science and the product.”

TTFields therapy, developed by Dr. Yoram Palti, now a retired Technion professor, is delivered via a non-invasive electrode device attached to the patient’s scalp. The low-intensity alternating electric fields have been clinically proven to slow and even reverse tumor growth by inhibiting the process of cells division and replication.

“If you think of standard cancer therapy – surgery, radiation and chemo – TTFields can be considered the fourth modality to be used independently or added to the other modalities to achieve better outcomes,” says Kirson. “As we move forward and do more clinical trials, we believe that it may be widely applicable in many types of cancer.”

[Photo: ODN / YouTube]